By a News Reporter-Staff News Editor at Drug Week DALLAS, One month after generic versions of three widely-used blood pressure drugs became available in Canada, hospital visits for adverse events spiked in generic drug users, according to new research in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association journal.
The company has commercial operations in 35 countries with 2,800 employees and operates four manufacturing and development hubs in the US, Romania, Korea and Taiwan. North America is Alvogen's single largest market and other key markets include: South Korea, Russia, Hungary, Romania, Taiwan, Ukraine, Japan and China. A consortium of investors, led
The European Federation of Pharmaceutical Industries and Associations issued the following news release:. With over 7000 medicines in development, new treatments will continue to change patients' lives; slowing disease progression, avoiding illness and reducing overall costs for healthcare systems. But developing a new medicines is a long, complex
By a News Reporter-Staff News Editor at Drug Week Dr. Reddy's Laboratories Ltd. announced that it has launched Sevelamer Carbonate Tablets, 800 mg, a therapeutic equivalent generic version of Renvela Tablets, approved by the U.S. Food and Drug Administration. "We are very pleased to bring Sevelamer Carbonate Tablets to market at this time," s
According to news reporting originating from New York City, New York, by NewsRx correspondents, research stated, "Biosimilar drugs are highly similar to an originator biologic, with no clinically meaningful differences in terms of safety or efficacy. Financial support for this research came from Pfizer. Our news editors obtained a quote from the re
In a latest submission, the industry told the Department of Pharmaceuticals that total margin of 35 per cent on branded drugs is an ideal number, said a senior official from the department. The government began thinking about capping trade margin of drugs in 2015 after the Maharasthra Food and Drug Administration raised a complaint against a cough
Swiss pharmaceutical giant Novartis AG (ADR)(NYSE:NVS) has announced that it will lay off 450 workers in the U.S. in the course of the next two years as it moves to gradually close down its generics manufacturing facility which is located in the state of Colorado. This comes at a time when the drugmaker is facing [?]
The post Novartis AG (ADR)(NY
The "The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis" report has been added to Research and Markets' offering. The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6 bn in 2016 is projected to almost double during the forecast period to reach $12.9 bn in 2021 driven by safety and effi
The "The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis" report has been added to Research and Markets' offering.. Major Takeaways The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6 bn in 2016 is projected to almost double during the forecast period to reach $12.9 bn in 2021 driven
CAMBRIDGE, England& HENNIGSDORF, Germany Abzena plc, the life sciences group providing integrated solutions and technologies enabling the development and manufacture of biopharmaceutical products, and UGA Biopharma GmbH, a cell line development specialist, announce the completion of the development of a biosimilar cell line to treat Multiple Sc
Aurobindo Pharma Limited is pleased to announce that the company has received final approval from the US Food& Drug Administration to manufacture Esomeprazole Magnesium Delayed-Release Capsules OTC, 20 mg. Aurobindo Pharma Limited, headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients.
Investor's Business Daily reported that 35 years after the first FDA- approved biotech drug, the Biotech industry is rolling out innovations at a breakneck pace. In today's pre-market research, DailyStockTracker.com redirects investors' attention to the performance of the following equities: Coherus Biosciences Inc., Exelixis Inc., Geron Corp., and
It has been asked throughout history: Haven't Native American tribes suffered enough? In September, the drug maker Allergan gave six patents for the drug Restasis to the upstate New York- based Saint Regis Mohawk Tribe, and paid the tribe $13.5 million to accept the patents and grant an exclusive license, also promising $15 million annually until t
LONDON, UK/ ACCESSWIRE/ October 19, 2017/ Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Impax Laboratories, Inc., following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/? Impax and Amneal Pharmaceuticals LLC, one of the largest and fastest
The Federal Trade Commission issued the following news release:. The workshop, titled "Understanding Competition in Prescription Drug Markets: Entry and Supply Chain Dynamics," will take place on November 8, 2017 at the FTC's Constitution Center Auditorium, 400 7th St., SW, Washington, DC. Acting FTC Chairman Maureen K. Ohlhausen and U.S. Food and
EVENT: Health and Human Services Department; Food and Drug Administration holds a workshop titled "Topical Dermatological Generic Drug Products: Overcoming Barriers to Development and Improving Patient Access," to provide an overview of current regulatory science initiatives related to generic topical dermatological drug products.
SMi Group has announced that Mr Patrick Lucy, CEO of Pfenex, has joined the speaker line-up for the 4th annual Biosimilars North America conference which takes place on November 15& 16 in New Jersey. In the run-up to the conference, SMi Group had a quickfire interview with Patrick Lucy. He will also share some top tips on what to keep in mind mov
Nexus Pharmaceuticals announced today the immediate availability in the United States of Procainamide HCL Injection, USP. "The introduction of Procainamide HCL Injection, USP further illustrates Nexus Pharmaceuticals' commitment to meeting market needs and shortages in the short term, while broadening the availability of effective generic produc
Novum Pharmaceutical Research Services, a leading U.S. contract research organization, has selected TrialMaster electronic data capture technology from OmniComm Systems, Inc.,, a leading global provider of clinical data management technology. Founded in 1972, the Pittsburgh- based CRO conducts Phase I to Phase IV complex generic and new drug clin
Table of Contents Office of the Federal Register Agriculture Department SeeGrain Inspection, Packers and Stockyards Administration SeeRural Utilities Service NOTICES Agency Information Collection Activities; Proposals, Submissions, and Approvals: Fast Track Generic Clearance for Collection of Qualitative Feedback on Customer Satisfaction...
This Wednesday morning, DailyStockTracker.com looks at the performance of these four Drugs- Generic stocks: pSivida Corp., Tetraphase Pharmaceuticals Inc., Catalent Inc., and Lannett Co. Inc.. On Tuesday, shares in Watertown, Massachusetts headquartered pSivida Corp. recorded a trading volume of 671,482 shares, which was above their three months av
Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food& Drug Administration for Aprepitant Capsules USP, 40 mg, 80 mg, and 125 mg, the generic version of Emend Capsules, 40 mg, 80 mg, and 125 mg, of Merck Sharp& Dohme Corporation. According to IMS Health sales data for the 12 month period ending August 2017, th
On October 17, 2017, Neos Therapeutics, Inc. entered into a confidential Settlement and Licensing Agreement with Actavis Laboratoris FL, Inc.. This Agreement resolves all ongoing litigation involving the Company's patents protecting its Adzenys XR-ODT extended-release orally disintegrating tablets and Actavis's Abbreviated New Drug Application..
According to report published by Grand View Research, The Global Specialty Generics Market size was estimated at USD 30.0 billion in 2016. The Global Specialty Generics Market is expected to reach USD 174.9 billion by 2025, according to a new report by Grand View Research, Inc. Rise in demand for low-cost generic specialty drugs is a major factor e
The new report from MP Advisors titled "The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis" examines in detail the current treatment landscape and the outlook through 2021 of psoriasis treatment market facing the U.S. Biologics and the Biosimilars. The report is authored by a seasoned Analyst with experience of over 15